NDAORALTABLET
Approved
Aug 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AQUATAG (benzthiazide) is an oral thiazide diuretic approved in 1965 for management of hypertension and edema. As a small-molecule diuretic, it works by inhibiting sodium reabsorption in the distal convoluted tubule, reducing blood volume and lowering blood pressure. This is a legacy antihypertensive with established clinical utility in older patient populations.
LOE Approaching
Product is in LOE phase with moderate competitive pressure (30), suggesting a mature, shrinking team focused on defensive strategy and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AQUATAG offers minimal career momentum given zero linked job openings and LOE status; roles focus on compliance, cost management, and smooth transition to generic market. This is a consolidation/wind-down assignment, not a growth opportunity.
Regulatory Affairs SpecialistProduct Manager (Legacy/Generic)
Worked on AQUATAG at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.